Phase 3 Clinical Trials With Primary Completion Dates in April 2024

This is a list of Phase 3 trials with primary completion dates in April 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AGIO Agios Pharmaceuticals, Inc. 2024-04-01 Phase 3 NCT04770779 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
ARWR Arrowhead Pharmaceuticals, Inc. 2024-04-01 Phase 3 NCT05089084 Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS)
CORT Corcept Therapeutics Incorporated 2024-04-01 Phase 3 NCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
EYPT EyePoint Pharmaceuticals, Inc. 2024-04-01 Phase 3 NCT05550350 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
FSPKF Fisher & Paykel Healthcare Corporation Limited 2024-04-01 Phase 3 NCT05505279 Ventilatory Effects of THRIVE During EBUS
IMVT Immunovant, Inc. 2024-04-01 Phase 3 NCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
OPHLY Ono Pharmaceutical Co., Ltd. 2024-04-01 Phase 3 NCT03036098 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
RIGL Rigel Pharmaceuticals, Inc. 2024-04-01 Phase 3 NCT04138927 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
SHIEF Shield Therapeutics plc 2024-04-01 Phase 3 NCT05126901 Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
VNDA Vanda Pharmaceuticals Inc. 2024-04-01 Phase 3 NCT05903924 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
ZLDPF Zealand Pharma A/S 2024-04-01 Phase 3 NCT03941236 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism